

NARCAN[®] (naloxone HCl) **NASAL SPRAY 4mg**

The **FIRST** and **ONLY**
FDA-Approved intranasal
naloxone for emergency
treatment of opioid overdose¹

Please see Indications and
Important Safety Information below

Not a substitute for emergency medical care



• Prefilled 4 mg unit dose:
No assembly needed

• No needles

• No special training
required.

Administer in accordance
with Instructions for Use

Provide the right treatment...
at the right place...at the right time.

Order Today. Call 1-844-4-NARCAN or 1-844-462-7226

For more information go to NarcanNasalSpray.com

INDICATIONS AND IMPORTANT SAFETY INFORMATION

INDICATIONS

NARCAN[®] (naloxone hydrochloride) Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. NARCAN[®] Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present.

NARCAN[®] Nasal Spray is not a substitute for emergency medical care.

IMPORTANT SAFETY INFORMATION

NARCAN[®] Nasal Spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride.

Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance.

Please see additional Important Safety Information on reverse side.

NARCAN[®] (naloxone HCl) **NASAL SPRAY 4mg**

Ordering Information

NARCAN [®] Nasal Spray	NDC# 69547-0353-02
Wholesaler	Item#
Amerisource Bergen	10162640
Cardinal	5204037
H.D. Smith	5525191
McKesson	3519402

The majority of opioid overdose related deaths occur outside the medical setting.² NARCAN[®] Nasal Spray requires no specialized training and can be administered by anyone.

Administer in accordance with Instructions for Use

Current Partnerships

In response to the growing opioid overdose crisis in communities across the nation, Adapt Pharma partners with state and local communities and organizations support efforts to:

- Educate on curbing opiate abuse and the appropriate use of opioid prescription medications
- Implement scaled-up naloxone access and distribution policies



U.S. COMMUNITIES[™]
GOVERNMENT PURCHASING ALLIANCE



Smith Medical Partners

IMPORTANT SAFETY INFORMATION (continued)

Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer repeat doses of naloxone using a new nasal spray with each dose, as necessary, while awaiting emergency medical assistance.

Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.

Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid dependent may precipitate opioid withdrawal characterized by body aches, diarrhea, increased heart rate (tachycardia), fever, runny nose, sneezing, goose bumps (piloerection), sweating, yawning, nausea or vomiting, nervousness, restlessness or irritability, shivering or trembling, abdominal cramps, weakness, and increased blood pressure. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated and may be characterized by convulsions, excessive crying, and hyperactive reflexes. Monitor for the development of opioid withdrawal.

Risk of Cardiovascular (CV) Effects: Abrupt postoperative reversal of opioid depression may result in adverse CV effects. These events have primarily occurred in patients who had pre-existing CV disorders or received other drugs that may have similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.

The following adverse reactions were observed in a NARCAN[®] Nasal Spray clinical study: increased blood pressure, musculoskeletal pain, headache, nasal dryness, nasal edema, nasal congestion, and nasal inflammation.

Please see accompanying full Prescribing Information.

For more information about NARCAN[®] Nasal Spray, please visit www.NarcanNasalSpray.com. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.

Reference: 1. Adapt Pharmaceuticals. Prescribing Information for NARCAN[®] Nasal Spray. Revised April, 2016. 2. CDC Wonder Database Multiple Cause of Death MCD - ICD-10 Codes: T40.1 (Heroin), T40.2 (Other opioids), T40.3 (Methadone), T40.4 (Other synthetic narcotics) 2013.



Find us on YouTube



Download the NARCAN[®] Now App



Visit NarcanNasalSpray.com

© 2016 ADAPT Pharma, Inc. NARCAN[®] is a registered trademark licensed to ADAPT Pharma Operations Limited. NAR4-45-16
Adapt Pharma, Inc. Radnor, PA

ADAPT
PHARMA

DOCKET
ALARM

Find authenticated court documents without watermarks at docketalarm.com.